Electronic Resource
To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question
| العنوان: | To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question |
|---|---|
| المؤلفون: | Lukasik, Zuzanna, Carron, Philippe, Webers, Casper |
| المصدر: | Best Practice & Research: Clinical Rheumatology vol.37 (2023) nr.3 |
| بيانات النشر: | 2023 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | The 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) propose to consider dose reduction of biological disease-modifying antirheumatic drugs (bDMARDs) for patients in sustained remission. However, this recommendation does not offer clear guidance for daily clinical practice. In this review, we analyze randomized clinical trials and real-world data on tapering and discontinuation of bDMARDs in patients with axSpA. We discuss the scientific rationale and benefits of tapering, identify advice to apply tapering in current practice, and delineate aspects to be investigated in future research. |
| مصطلحات الفهرس: | Axial spondyloarthritis, Biological DMARD, Discontinuation, Remission, Tapering, Therapy, (Systematic) Review article |
| URL: | |
| الاتاحة: | Open access content. Open access content |
| ملاحظة: | DOI: 10.1016/j.berh.2023.101869 English |
| Other Numbers: | NLMAT oai:cris.maastrichtuniversity.nl:publications/7f6b1cb4-a123-4d92-bf82-9e052bddbf90 https://cris.maastrichtuniversity.nl/en/publications/7f6b1cb4-a123-4d92-bf82-9e052bddbf90 1427435645 |
| المصدر المساهم: | UNIVERSITEIT MAASTRICHT From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1427435645 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |